ACCESSIBILITY

24/7

Headlines

21:39

Full list of Israeli high-tech layoffs in 2026

21:36

Remitly cuts 110 jobs in Israel and closes R&D hub three years after $80 million Rewire acquisition

16:41

Rigas: "Energean needs more gas to compete, and to prevent a monopoly"

16:31

“When you raise walls around data, employees go around them”

Buzz

Most popular

Daily

Weekly

Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”

Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race

Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion

After $400M cyber exit, ex-IntSights CEO raises $11M to build AI app for personalized sports highlights

“SaaS is dying as a business category”

More news

Biomed

9 stories about Biomed

Fourth Time’s the Charm for Entera Bio IPO

01.07.18|Dror Reich

The Israel-based oral drug developer listed on Nasdaq on Thursday, pricing 1.4 million units of one share and one warrant at $8 each

Entera Bio Gives Nasdaq IPO Another Shot

21.05.18|Dror Reich

This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq

Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange

29.04.18|Racheli Bindman

Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April

An Israeli Company Wants to Treat Tourette Syndrome With Cannabis

09.04.18|Lilach Baumer

Therapix Biosciences announced the successful completion of phase 2 clinical trial of its cannabinoid-based drug, conducted at Yale University Monday

For the Fourth Time, Entera Bio Tries for Nasdaq IPO

08.01.18|Dror Reich

The Jerusalem-based biomed company plans to raise $55 million, with Oppenheimer & Co. as the sole underwriter

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich

The Israel-based NYSE American-listed company is currently undergoing a streamlining process

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer

The clinical stage company develops treatments mostly for osteoporosis and bone disorders

Collplant Takes a Step Towards 3D Organ Printing

17.10.17|Lilach Baumer

The Israel-based company develops collagen-based biological ink for 3D organ printing

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich

Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism